Sanying Biotechnology

Wuhan Sanying Biotechnology Co., Ltd. is a wholly-owned subsidiary of the American antibody brand PROTEINTECH GROUP, which began operations in 2002. The company's goal is to implement the Human Antibody Initiative, namely to research and prepare antibodies against all proteins in the human proteome, explore new technologies for large-scale antibody production, and improve high-throughput, automated, and intelligent detection technologies for antigen-antibody interactions. The company possesses more than 20,000 human full-length cDNA clones, has expressed and purified more than 12,000 fusion proteins using genetic engineering methods, and has produced and processed more than 12,000 antibodies. The company is currently selling more than 10,000 types of detected and purified antibodies.
Wuhan Sanying Biotechnology Co., Ltd. is located in the Biopark of Wuhan East Lake New Technology Development Zone, equipped with a large-scale experimental animal base. The company has a comprehensive online product database system and ordering system, with companies in the United States and the United Kingdom, and a dedicated distributor in Japan. The company's own brand Proteintech is renowned in the international antibody field and widely recognized in the biomedical fields of the United States, Japan, and European countries. Customers have published 2,500 articles using the company's products, and the number is steadily increasing.

The company's new laboratory building has been completed in the Biopark of Wuhan East Lake Development Zone. The company sincerely invites aspiring individuals to join, offering generous compensation, comprehensive career development channels, and complete social insurance, housing provident fund, paid annual leave, holiday benefits, and other protections. The specific work content and responsibilities of each position are detailed in the company's job descriptions.